Recipient B cells are not required for graft-versus-host disease induction

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 9, 2010, Pages 1222-1230

  Matte Martone, Catherine ^a,b   Wang, Xiajian ^c   Anderson, Britt ^b   Jain, Dhanpat ^b   Demetris, Anthony J ^d   McNiff, Jennifer ^b   Shlomchik, Mark J ^b   Shlomchik, Warren D ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZHEJIANG UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presenting cells; B cells; Graft versus host disease; GVHD

Indexed keywords

RITUXIMAB;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON; GRAFT VERSUS HOST REACTION; LIVER; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; SPLEEN;

EID: 77955513410     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.015     Document Type: Article

References (53)

1. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
2. Anderson B.E., McNiff J.M., Jain D., Blazar B.R., Shlomchik W.D., Shlomchik M.J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005, 105:2227-2234.
3. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
4. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
5. Duffner U.A., Maeda Y., Cooke K.R., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004, 172:7393-7398.
6. Schultz K.R., Paquet J., Bader S., HayGlass K.T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289-295.
7. Maloney D.G. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999, 26:74-78.
8. Edwards J.C., Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006, 6:394-403.
9. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
10. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
11. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
12. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
13. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001, 98:3595-3599.
14. Zhong G., Reis e Sousa C., Germain R.N. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med 1997, 186:673-682.
15. Bogen B., Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol 1993, 10:337-355.
16. Sant A.J. Endogenous antigen presentation by MHC class II molecules. Immunol Res 1994, 13:253-267.
17. Brooks A.G., McCluskey J. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells. J Immunol 1993, 150:3690-3697.
18. Munthe L.A., Kyte J.A., Bogen B. Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo. Eur J Immunol 1999, 29:4043-4052.
19. Constant S., Schweitzer N., West J., Ranney P., Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 1995, 155:3734-3741.
20. Croft M., Duncan D.D., Swain S.L. Response of naive antigen-specific CD4+ T cells in vitro: characteristics and antigen-presenting cell requirements. J Exp Med 1992, 176:1431-1437.
21. Croft M., Bradley L.M., Swain S.L. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994, 152:2675-2685.
22. Ron Y., Sprent J. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol 1987, 138:2848-2856.
23. Ke Y., Kapp J.A. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J Exp Med 1996, 184:1179-1184.
24. Yefenof E., Zehavi-Feferman R., Guy R. Control of primary and secondary antibody responses by cytotoxic T lymphocytes specific for a soluble antigen. Eur J Immunol 1990, 20:1849-1853.
25. Barnaba V., Franco A., Alberti A., Benvenuto R., Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 1990, 345:258-260.
26. Shen H., Whitmire J.K., Fan X., Shedlock D.J., Kaech S.M., Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol 2003, 170:1443-1451.
27. Epstein M.M., Di Rosa F., Jankovic D., Sher A., Matzinger P. Successful T cell priming in B cell-deficient mice. J Exp Med 1995, 182:915-922.
28. Asano M.S., Ahmed R. CD8 T cell memory in B cell-deficient mice. J Exp Med 1996, 183:2165-2174.
29. Bennett S.R., Carbone F.R., Toy T., Miller J.F., Heath W.R. B cells directly tolerize CD8(+) T cells. J Exp Med 1998, 188:1977-1983.
30. Fuchs E.J., Matzinger P. B cells turn off virgin but not memory T cells. Science 1992, 258:1156-1159.
31. Hollsberg P., Batra V., Dressel A., Hafler D.A. Induction of anergy in CD8 T cells by B cell presentation of antigen. J Immunol 1996, 157:5269-5276.
32. Fu Y.X., Huang G., Wang Y., Chaplin D.D. B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med 1998, 187:1009-1018.
33. Ngo V.N., Korner H., Gunn M.D., et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999, 189:403-412.
34. Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., Cyster J.G. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005, 22:439-450.
35. Kitamura D., Rajewsky K. Targeted disruption of mu chain membrane exon causes loss of heavy-chain allelic exclusion. Nature 1992, 356:154-156.
36. Chen J., Trounstine M., Alt F.W., et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993, 5:647-656.
37. Ahuja A., Shupe J., Dunn R., Kashgarian M., Kehry M.R., Shlomchik M.J. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007, 179:3351-3361.
38. Anderson B.E., McNiff J., Yan J., et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003, 112:101-108.
39. Matte-Martone C., Liu J., Jain D., McNiff J., Shlomchik W.D. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 2008, 111:3884-3892.
40. Beilhack A., Schulz S., Baker J., et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 2008, 111:2919-2928.
41. Anderson B.E., Taylor P.A., McNiff J.M., et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 2008, 111:5242-5251.
42. Hamilton B.L., Bevan M.J., Parkman R. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. J Immunol 1981, 126:621-625.
43. Kaplan D.H., Anderson B.E., McNiff J.M., Jain D., Shlomchik M.J., Shlomchik W.D. Target antigens determine graft-versus-host disease phenotype. J Immunol 2004, 173:5467-5475.
44. Allman D.M., Ferguson S.E., Cancro M.P. Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J Immunol 1992, 149:2533-2540.
45. Allman D.M., Ferguson S.E., Lentz V.M., Cancro M.P. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol 1993, 151:4431-4444.
46. Mizoguchi A., Bhan A.K. A case for regulatory B cells. J Immunol 2006, 176:705-710.
47. Hu C.Y., Rodriguez-Pinto D., Du W., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007, 117:3857-3867.
48. Rowe V., Banovic T., MacDonald K.P., et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006, 108:2485-2492.
49. Kebriaei P., Saliba R.M., Ma C., et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006, 38:203-209.
50. van Dorp S., Pietersma F., Wölfl M., et al. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009, 15:671-678.
51. Bellucci R., Alyea E.P., Chiaretti S., et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005, 105:3945-3950.
52. Zorn E., Miklos D.B., Floyd B.H., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004, 199:1133-1142.
53. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006, 107:2993-3001.